Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04586231 · ClinicalTrials.gov registry record · Phase 3
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
A Phase 3 study of Carcinoma, Renal Cell, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 3
- Development phase
- 747
- Enrollment target
- 20
- Study locations
NCT04586231 is a Phase 3 study of Carcinoma, Renal Cell that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 747 participants, above the 261-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (186% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT04586231, a Phase 3 study of Carcinoma, Renal Cell, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 747 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progression-free survival or overall survival.
Conditions Studied
Interventions
- DRUG Belzutifan
- DRUG Cabozantinib
- DRUG Lenvatinib
Study Locations (20)
California
- Cedars Sinai Medical Center ( Site 0027) - Los Angeles
- UCLA Hematology/Oncology - Santa Monica ( Site 0048) - Los Angeles
- St. Joseph Hospital-The Center for Cancer Prevention and Treatment ( Site 0095) - Orange
- UC Irvine Health ( Site 0029) - Orange
- Providence Saint John's Health Center ( Site 0083) - Santa Monica
Florida
- AdventHealth Orlando-AdventHealth Medical Group Hematology & Oncology at Orlando ( Site 0003) - Orlando
- Orlando Health, Inc. ( Site 0035) - Orlando
Georgia
- University Cancer & Blood Center, LLC ( Site 0057) - Athens
- Emory University Hospital ( Site 0012) - Atlanta
Illinois
- Rush University Medical Center ( Site 0040) - Chicago
- Illinois Cancer Care, PC ( Site 0008) - Peoria
Arizona
- Ironwood Cancer & Research Centers ( Site 0077) - Chandler
District of Columbia
- Georgetown University Medical Center ( Site 0006) - Washington D.C.
Indiana
- Parkview Cancer Institute ( Site 0088) - Fort Wayne
Kentucky
- Norton Cancer Institute - St. Matthews ( Site 0065) - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 747 participants |
| Start Date | 2021-02-25 |
| Est. Completion | 2027-02-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04586231
The ClinicalTrials.gov registry entry for NCT04586231 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 747 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 261-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (186% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 3 interventions - of which Belzutifan is the first listed.
NCT04586231 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT04586231 about?
NCT04586231 is a clinical study titled "A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)". This study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantinib in terms of progr...
What is the current status of trial NCT04586231?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 747 participants. The study started on 2021-02-25. Estimated completion is 2027-02-11.
What conditions does trial NCT04586231 study?
This clinical trial studies the following conditions: Carcinoma, Renal Cell.
What interventions are being tested in trial NCT04586231?
The interventions under investigation include: Belzutifan (DRUG), Cabozantinib (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT04586231?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04586231 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Renal Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Savolitinib vs. Sunitinib in MET-driven PRCC.
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
ACTIVE NOT RECRUITING · Phase 3
-
SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
COMPLETED · Phase 3
-
Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.